Evaluation of PMI-5011, an ethanolic extract of Artemisia dracunculus L., on peripheral neuropathy in streptozotocin-diabetic mice

International Journal of Molecular Medicine

Volumn 27, Issue 3, 2011, Pages 299-307

  Watcho, Pierre ^a,b   Stavniichuk, Roman ^a   Tane, Pierre ^b   Shevalye, Hanna ^a   Maksimchyk, Yury ^a   Pacher, Pal ^c   Obrosova, Irina G ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF DSCHANG   (Cameroon)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Diabetic neuropathy; Oxidative nitrosative stress; PMI 5011

Indexed keywords

ALCOHOL; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARTEMISIA DRACUNCULUS EXTRACT; PLANT EXTRACT; PMI 5011; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTEMISIA; ARTEMISIA DRACUNCULUS; ARTICLE; BODY WEIGHT; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFICACY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID DIET; MOUSE; NERVE CONDUCTION; NITROSATIVE STRESS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCIATIC NERVE; SPINAL CORD; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; ARTEMISIA; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIETARY FATS; EPIDERMIS; HYPERALGESIA; HYPERGLYCEMIA; LIPOXYGENASE; MICE; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; SCIATIC NERVE; SPINAL CORD;

EID: 79551578269     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.597     Document Type: Article

References (45)

1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM and Ziegler D: American Diabetes Association: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28: 956-962, 2005.
2. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L and Valensi P: Toronto Diabetic Neuropathy Expert Group: Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33: 2285-2293, 2010.
3. Calcutt NA: Experimental models of painful diabetic neuropathy. J Neurol Sci 220: 137-139, 2004.
4. Veves A, Backonja M and Malik RA: Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 9: 660-674, 2008.
5. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N and Shigeta Y: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29: 1538-1544, 2006.
6. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J and Samigullin R: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29: 2365-2370, 2006.
7. Ribnicky DM, Poulev A, O'Neal J, Wnorowski G, Malek DE, Jäger R and Raskin I: Toxicological evaluation of the ethanolic extract of Artemisia dracunculus L. for use as a dietary supplement and in functional foods. Food Chem Toxicol 42: 585-598, 2004.
8. Ribnicky DM, Poulev A, Watford M, Cefalu WT and Raskin I: Antihyperglycemic activity of Tarralin, an ethanolic extract of Artemisia dracunculus L. Phytomedicine 13: 550-557, 2006.
9. Govorko D, Logendra S, Wang Y, Esposito D, Komarnytsky S, Ribnicky D, Poulev A, Wang Z, Cefalu WT and Raskin I: Polyphenolic compounds from Artemisia dracunculus L. inhibit PEPCK gene expression and gluconeogenesis in an H4IIE hepatoma cell line. Am J Physiol Endocrinol Metab 293: 1503-1510, 2007.
10. Wang ZQ, Ribnicky D, Zhang XH, Raskin I, Yu Y and Cefalu WT: Bioactives of Artemisia dracunculus L enhance cellular insulin signaling in primary human skeletal muscle culture. Metabolism 57: 58-64, 2008.
11. Wang ZQ, Ribnicky D, Zhang XH, Zuberi A, Raskin I, Yu Y and Cefalu WT: An extract of Artemisia dracunculus L. enhances insulin receptor signaling and modulates gene expression in skeletal muscle in KK-A(y) mice. J Nutr Biochem: May 4, 2010 (Epub ahead of print).
12. Logendra S, Ribnicky DM, Yang H, Poulev A, Ma J, Kennelly EJ, and Raskin I: Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus. Phytochemistry 67: 1539-1546, 2006.
13. Watcho P, Stavniichuk R, Ribnicky DM, Raskin I and Obrosova IG: High-fat diet-induced neuropathy of prediabetes and obesity: effect of PMI-5011, an ethanolic extract of Artemisia dracunculus L. Mediators Inflamm 2010: 268547, 2010.
14. Kheterpal I, Coleman L, Ku G, Wang ZQ, Ribnicky D and Cefalu WT: Regulation of insulin action by an extract of Artemisia dracunculus L. in primary human skeletal muscle culture: a proteomics approach. Phytother Res 24: 1278-1284, 2010.
15. Francis G, Martinez J, Liu W, Nguyen T, Ayer A, Fine J, Zochodne D, Hanson LR, Frey WH II and Toth C: Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes 58: 934-945, 2009.
16. Cameron NE, Cotter MA, Basso M and Hohman TC: Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40: 271-281, 1997.
17. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS and Chung SK: Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55: 1946-1953, 2006.
18. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N and Hotta N: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48: 2090-2095, 1999.
19. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA and Stevens MJ: An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16: 123-125, 2002.
20. Yagihashi S, Yamagishi SI, Wada Ri R, Baba M, Hohman TC, Yabe-Nishimura C and Kokai Y: Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124: 2448-2458, 2001.
21. Cameron NE, Tuck Z, McCabe L and Cotter MA: Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 44: 1161-1169, 2001.
22. Low PA, Nickander KK and Tritschler HJ: The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46: 38-42, 1997.
23. Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H and Low PA: Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18: 1160-1167, 1995.
24. Obrosova IG, Mabley JG, Zsengellér Z, Charniauskaya T, Abatan OI, Groves JT and Szabó C: Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19: 401-403, 2005.
25. Stevens MJ, Obrosova I, Cao X, Van Huysen C and Greene DA: Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49: 1006-1015, 2000.
26. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider JG, Schulz JB, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Haering HU, Schleicher E, Kasper M, Stern DM, Arnold B and Nawroth PP: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114: 1741-1751, 2004.
27. Cameron NE and Cotter MA: Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 9: 60-67, 2008.
28. Kumar A and Sharma SS: NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 394: 360-365, 2010.
29. Wang Y, Schmeichel AM, Iida H, Schmelzer JD and Low PA: Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J Neurol Sci 247: 47-52, 2006.
30. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjáti K, Pacher P Szabó C and Stevens MJ: Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53: 711-720, 2004.
31. Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT and Yorek MA: Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 293: 1645-1655. 2007.
32. Obrosova IG, Xu W, Lyzogubov VV, Ilnytska O, Mashtalir N, Vareniuk I, Pavlov IA, Zhang J, Slusher B and Drel VR: PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 44: 972-981, 2008.
33. Obrosova IG, Van Huysen C, Fathallah L, Cao X, Stevens MJ and Greene DA: Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 14: 1548-1558, 2000.
34. Stavniichuk R, Drel VR, Shevalye H, Vareniuk I, Stevens MJ, Nadler JL and Obrosova IG: Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radic Biol Med 49: 1036-1045, 2010.
35. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH and Lachin JM: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33: 1090-1096, 2010.
36. Turner RC and Holman RR: Lessons from UK prospective diabetes study. Diabetes Res Clin Pract 28: 151-157, 1995.
37. Varma SD and Kinoshita JH: Inhibition of lens aldose reductase by flavonoids - their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 25: 2505-2513, 1976.
38. Obrosova IG, Stavniichuk R, Drel VR, Shevalye H, Vareniuk I, Nadler JL and Schmidt RE: Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am J Pathol 177: 1436-1447, 2010.
39. Natarajan R and Nadler JL: Lipoxygenases and lipid signaling in vascular cells in diabetes. Front Biosci 8: 783-795, 2003.
40. Natarajan R and Nadler JL: Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24: 1542-1548, 2004.
41. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD and Yorek MA: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50: 1927-1937, 2001.
42. Coppey LJ, Gellett JS, Davidson EP and Yorek MA: Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37: 33-40, 2003.
43. Coppey LJ, Davidson EP, Rinehart TW, Gellett JS, Oltman CL, Lund DD and Yorek MA: ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 55: 341-348, 2006.
44. Naruse K, Hamada Y, Nakashima E, Kato K, Mizubayashi R, Kamiya H, Yuzawa Y, Matsuo S, Murohara T, Matsubara T, Oiso Y and Nakamura J: Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 54: 1823-1828, 2005.
45. Obrosova IG: Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6: 638-647, 2009.